Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2018 Investor Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Ironwood Pharma (IRWD) Surges 12% Following Results/Outlook
February 13, 2019 10:02 AM ESTIronwood Pharma (NASDAQ: IRWD) is gaining 12% in early following better-than-expected Q4 results and guidance.
... MoreIronwood Pharma (IRWD) Tops Q4 EPS by 5c, Revenues Beat; Offers FY19 Revenue Mid-Point Guidance Above Consensus
February 13, 2019 7:05 AM ESTIronwood Pharma (NASDAQ: IRWD) reported Q4 EPS of ($0.10), $0.05 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $130.69 million versus the consensus estimate of $96.57 million.
The fourth quarter capped off a year of solid LINZESS volume growth and progress with our pipeline of seven differentiated product candidates, said... More
